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Abstract

Aim: To identify demographic, behavioral, and interpersonal characteristics associated with
hepatitis C (HCV) serostatus disclosure among adult, rural, high-risk people who use drugs
(PWUD) in Appalachian Kentucky.
Methods: HCV antibody-positive participants (n=243), drawn from the fifth follow-up
assessment of a longitudinal study of rural PWUD, completed interviewer-administered
questionnaires eliciting demographic and interpersonal characteristics, risk behaviors, and
information on HCV disclosure. Correlates of HCV disclosure were assessed using multivariate
logistic regression.
Results: Most (69.1%) reported disclosing their HCV-positive status to at least one of their
social referents (current or past sex partners, current or past injection drug use (IDU) partners,
family, friends, or spouse), but few told the people with whom they inject drugs (3.8% disclosed
to current, and 1.4% disclosed to past IDU partners). In multivariate analysis, adjusting for
confounders and time since HCV diagnosis, older age (AOR=0.96, 95% CI [0.93, 1.00]) and
lifetime history of drug treatment (AOR=0.39, 95% CI [0.22, 0.69]) were associated with
decreased odds of HCV disclosure.
Conclusions: While most participants reported HCV disclosure, the almost complete absence of
disclosure to current or former injection drug use partners was concerning. Although further
research is warranted, it is clear that interventions are needed to encourage HCV disclosure
among those most at risk of transmitting, or becoming infected with, HCV.
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Introduction

Current estimates suggest that at least 3.5 million individuals (range 2.5 million – 4.7 million)1
are infected with hepatitis C virus (HCV) in the United States, making HCV the most common
blood-borne infection in the United States. The Centers for Disease Control and Prevention
(CDC) estimates that nearly 30,000 incident cases of acute HCV occurred in 2013 in the United
States.2 Between 2006-2012, state surveillance data from Central Appalachia (Kentucky,
Tennessee, Virginia, and West Virginia) demonstrated a 364% increase in the number of acute
HCV infections among persons ≤30 years old.3 Among those cases of acute HCV in Central
Appalachia with identified risk information, injection drug use (IDU) was reported in almost
three-fourths of cases (73%).3 HCV is primarily transmitted through percutaneous exposure to
contaminated blood. As a consequence, IDU is the leading means of HCV transmission in the
United States.4,5 Despite the existence of national screening recommendations based on risk
factors and birth cohort, many individuals are unaware that they are infected with HCV. Several
recent studies suggest that a substantial proportion (40-85%) of HCV-positive individuals are
unaware of their infection status.4 One study found that among persons who inject drugs
(PWID), 72% of those who were HCV-positive were unaware of their status.6

Individuals with both acute and chronic HCV infections are often asymptomatic.7,8
Consequently, many HCV-infected individuals never seek testing. These factors contribute to the
substantial lack of awareness of serostatus among HCV-positive individuals, which places risk
partners (particularly people with whom they inject or share injection equipment) of infected
individuals at risk of unwittingly acquiring HCV. Although highly successful curative treatments
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have been developed in recent years, these medications are prohibitively expensive.9 Among
high-risk populations (such as PWID) that frequently lack access to health insurance or
healthcare, reliance on curative medical treatment to stop the spread of HCV is not yet a viable
and scalable prevention strategy. Primary prevention of HCV infection is the most desirable
public health approach to reducing morbidity, mortality, and the economic burden associated
with HCV infection.

Serostatus disclosure has been described as a cornerstone of primary prevention strategies related
to human immunodeficiency virus (HIV) transmission between sexual partners.10,11 HCV
disclosure can similarly serve as an important preventive public health measure for HCV
infection. Disclosure of HCV allows the social contacts of an infected individual the opportunity
to make informed decisions regarding engaging in risk behaviors, thus potentially reducing HCV
transmission risks. Research indicates that individuals who believe their injecting partner is
HCV-positive are more likely to practice safer injecting habits (i.e., not inject with someone
else’s used needle/syringe).12

While there have been numerous efforts to determine correlates of HIV disclosure,10,11,13-15
comparatively less research has been published investigating the factors associated with
disclosure of HCV. Additionally, studies examining disclosure of HIV more frequently focus on
serostatus disclosure among sexual partners; findings from this research may not be applicable to
understanding disclosure of HCV status given that sexual transmission of HCV is rare16 and
percutaneous transmission through shared needles or injection equipment among PWID is most
common.4,5,8 Similarly, the fact that HIV disclosure is mandatory in many settings17 while HCV
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disclosure is not suggests that the factors impacting HIV disclosure may differ from those
impacting HCV disclosure.

Social stigma surrounding disease status disclosure, particularly of infectious diseases perceived
as being acquired through stigmatized risk behaviors (e.g., illegal drug use), can negatively
impact access to health care, employment, and social support.18 HCV disclosure has been
described in the literature as a complex and emotionally difficult endeavor, with fear of a
negative reaction, rejection, or stigmatization commonly cited as barriers to HCV-positive status
disclosure.18,19 Studies among current PWID also found that PWID perceive HCV infection as
inevitable and ubiquitous,20 and suggested that this fatalistic attitude could result in ambivalence
about the need for HCV disclosure.21 Results from a cross-sectional survey in Australia revealed
that individuals who reported being advised by someone at the time of diagnosis to tell no one or
only close family members disclosed their HCV-positive status less widely than those who did
not receive the same advice,22 suggesting that social influences may have a profound impact on
an individual’s disclosure practice.

Much of the published literature related to HCV disclosure has been conducted internationally,
primarily among PWID in urban settings,18-20,22-26 and most of the studies anecdotally report
correlates of HCV disclosure rather than focusing on disclosure as the primary research outcome.
Relatively little is known about factors that influence HCV-positive disclosure among high-risk
populations in rural settings. Appalachian Kentucky is an economically disadvantaged region
that suffers from worse mortality rates among young and middle-aged adults than many less
developed countries.27 A recent study demonstrated that annual increases in acute HCV

4

incidence among young (30 years) PWID in the United States were at least twice as high in
rural jurisdictions as urban jurisdictions.28 The largest increases noted in the study were in rural
jurisdictions in or nearby Appalachian counties.28 When considered in combination with the
recent significant increase in acute HCV infections among persons 30 years in Kentucky,
Tennessee, Virginia, and West Virginia,3 the data suggest that Central Appalachia is a current
epicenter of HCV incidence in the United States. The purpose of this analysis is to identify
demographic, behavioral, and interpersonal characteristics associated with HCV serostatus
disclosure among rural, high-risk drug users in Appalachian Kentucky.

Methods

Study Design
Data were collected from drug users (n=415) completing their fifth follow-up assessment in the
ongoing, longitudinal Social Networks among Appalachian People (SNAP) study. The overall
goal of the SNAP study is to analyze risk factors for HIV, HCV, and HSV-2 in the context of
drug users’ social networks. Participants (n=503) were recruited through respondent-driven
sampling29,30 between November 2008 and September 2010 from an Appalachian county in
eastern Kentucky (explained in detail elsewhere31). Respondent-driven sampling has previously
been shown to be an effective technique for the recruitment of rural drug users.32 The original
participants, or seeds, were recruited through outreach workers, community informants, and
flyers posted at the study site, and had a lifetime history of IDU. Once the seeds completed their
baseline interviewer-administered questionnaire, they were given three coupons and asked to
recruit drug-using peers (irrespective of injection status).
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Individuals eligible for study participation were at least 18 years old, resided in Appalachian
Kentucky, and had used prescription opioids, cocaine, heroin, or methamphetamine to get high in
the prior 30 days. All participants received copies of the consent form and provided signed
documentation of informed consent. Participants were compensated for their time ($50), and
those seeds whose coupons were redeemed (i.e., by a peer who was eligible for, and completed
the baseline interviewer-administered questionnaire) received an additional $10 per redeemed
coupon. Participants completed interviewer-administered surveys and HCV testing
approximately every six months. For the baseline assessment and the first three follow-up visits,
trained study staff tested participants for antibodies to HCV using the Home Access test (Home
Access Health Corporation, Hoffman Estates, IL), explained in detail elsewhere.33 For all
subsequent visits participants were tested using the OraQuick HCV rapid antibody test.34 All
participants were provided with their test results, either in person or by telephone, and pre- and
posttest counseling was provided according to CDC guidelines. Participants who tested positive
for HCV were provided with information about local healthcare resources for additional testing
and treatment. The Institutional Review Board at the University of Kentucky approved the study
protocol.

A total of 415 participants (82.5% of the original sample) completed the fifth follow-up
assessment. Participants lost to follow-up were less likely to be unemployed (2=9.70, p=0.002)
than those retained in the study, but were otherwise not significantly different from those
remaining in the analysis in terms of demographic characteristics or HCV serostatus. For the
fifth follow-up assessment (3.8–5.3 years since participant enrollment), questions were added to
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examine whether participants who had tested HCV antibody-positive at baseline or at any point
during the study (n=243) had disclosed their HCV-positive status to others. Specifically,
participants were asked, “After testing positive (here–at this location) for hepatitis C did you tell
(please check all that apply): [your current sex partner, past sex partners, current injection drug
use partners (people you inject with), past injection drug use partners (people you inject with),
family member(s), close friend(s), spouse (if married)].”

To assess correlates of HCV disclosure, a dichotomous variable was created to indicate whether
or not participants disclosed their HCV-positive status to anyone. Dichotomization was
necessary because the limited number of participants disclosing to most of the identified persontype categories did not provide sufficient power to identify statistically significant differences in
demographic, behavioral, or interpersonal characteristics between those HCV-positive
individuals who had disclosed or had never disclosed their HCV-positive status by person-type.

Demographic, behavioral, and interpersonal data were also obtained through the intervieweradministered questionnaire. Demographic characteristics included gender, age (years), race,
education, marital status, and unemployment. Additional characteristics, including lifetime
history of IDU, lifetime history of drug treatment, and time since HCV diagnosis (years), were
also assessed. Finally, interpersonal characteristics included whether the participant: was
dependent on someone else for the majority of their support, self-reported spending most free
time alone (rather than with family or friends), and had significant periods experiencing serious
problems getting along with others during his/her lifetime. The latter interpersonal characteristic
was assessed with the question, “Have you had significant periods in which you have
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experienced serious problems getting along with your [mother, father, brothers/sisters, sexual
partner/spouse, children, close friends, neighbors, co-workers] in your life?” Data were
dichotomized to a negative response if participants denied serious problems with all possibly
identified social referents, and to an affirmative response if participants acknowledged serious
problems with any of the possibly identified social referents. The resultant covariate is hereafter
referred to as ‘social conflict.’

Analysis
Logistic regression was used to explore associations between HCV disclosure and demographic,
behavioral, and interpersonal characteristics. All analyses were conducted using SAS software,
version 9.4 (SAS Institute; Cary, NC, USA).35

A confounding analysis was completed to aid in covariate selection for the final model. Changes
in the estimated, unadjusted odds ratio between independent variables identified as being
associated with disclosure in the literature (e.g., gender and education)22,26 and through
univariate logistic regression analysis (e.g., lifetime history of drug treatment) and HCV
disclosure were examined in the presence and absence of other covariates that could act as
potential confounders. Confounding was considered present if the estimated, unadjusted odds
ratio changed by more than 15%. The confounding analysis identified lifetime history of drug
treatment as a positive confounder of the association between HCV disclosure and both gender
and education. Consequently, lifetime history of drug treatment was required to be in the final
model. Covariates in the initial multivariate model included gender, age, race, education, marital
status, unemployment, dependence on someone else for majority of support, lifetime history of
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IDU, spend most of free time alone, social conflict, lifetime history of drug treatment, and time
since HCV diagnosis. The final model was derived through manual backward elimination with
critical=0.05, and included age, lifetime history of drug treatment, and time since HCV diagnosis.

Respondent-driven sampling weights were not applied to the data because rather than calculating
population estimates of HCV disclosure, this study focused on correlates of HCV disclosure in
this sample of rural, high-risk drug users. Collinearity within the model was assessed in both the
full and final models using the %COLLIN_2011 macro.36 Covariates did not exceed a condition
index of 30 in either the full or final model, indicating that multicollinearity was not present in
either multivariate model.

Results

Participant Characteristics
Participants (n=243) were primarily male (57.2%), white (93.0%), and had at least a high school
education (54.3%). The mean age was 33.8 years (range 20.5-56.5). While all participants were
HCV antibody positive, only 32.9% sough confirmatory testing, and only 4.9% sought treatment
for HCV. Among those who sought confirmatory testing (n=80), the majority (85.0%) reported
testing positive on the second test and being told they have HCV. Most (77.0%) tested HCVpositive for the first time within the SNAP study. The median duration since HCV diagnosis was
8.8 years (IQR 5.9) and 4.2 years (IQR 1.4) for participants who tested positive prior to entering
the study and during the study, respectively; the overall mean duration since HCV diagnosis was
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5.0 years (range 0.4-22.3). Demographic, behavioral, and interpersonal characteristics are
presented in Table 1.

HCV-positive Status Disclosure and Correlates
Most participants (69.1%) reported disclosing their HCV-positive status to at least one of their
social referents (Table 2). Individuals who disclosed their HCV-positive serostatus most
commonly disclosed to current sex partners (63.7%), family members (51.8%), close friend(s)
(13.7%), or past sex partners (9.5%). Few participants disclosed to current IDU partners (3.8%,
calculated among 72 who reported injecting within the past six months), spouses (if married)
(2.9%), or past IDU partners (1.4%, calculated among 215 who reported ever injecting drugs).

Results from unadjusted logistic regression analyses are presented in Table 1. Estimated,
unadjusted odds ratios, 95% confidence intervals, and p-values are provided to show associations
between covariates and HCV-positive status disclosure. None of the demographic, behavioral, or
interpersonal characteristics assessed were significantly associated with HCV disclosure.
Lifetime history of drug treatment was significantly associated with non-disclosure of HCVpositive status. Participants with a lifetime history of drug treatment had 60% lesser odds of
disclosing their HCV-positive status than those participants who had no history of drug treatment
(odds ratio [OR]: 0.40; 95% CI [0.23, 0.70]). Of note, there was no evidence of a dose-response
relationship between weeks spent in drug treatment in the prior year and HCV disclosure (data
not shown in table).
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Table 3 presents the results from the final multivariate logistic regression model (n=243).
Adjusting for all other covariates in the model, age (p=0.043) and lifetime history of drug
treatment (p=0.001) were independently associated with HCV-positive status disclosure. Time
since HCV diagnosis (p=0.782) was maintained in the final model to control for the effects of
varying duration of serostatus awareness. Holding all other covariates constant, a one year
increase in age corresponded to a 4% reduction in the odds of disclosing HCV-positive status
(AOR: 0.96, 95% CI [0.93, 1.00]). A lifetime history of drug treatment corresponded to a 61%
reduction in the odds of disclosing HCV-positive status compared to participants without a
history of drug treatment, adjusting for the other covariates in the model (AOR: 0.39, 95% CI
[0.22, 0.69]).

Discussion

To the author’s knowledge, this is the first study of its kind to quantitatively assess correlates of
HCV serostatus disclosure among rural drug users. The purpose of this study was to identify
demographic, behavioral, and interpersonal characteristics associated with HCV disclosure
among high-risk drug users in Appalachian Kentucky. Notably, 30.9% of participants did not
disclose their HCV-positive status to anyone. Among individuals who did disclose their
serostatus, disclosure to those social referents potentially at greatest risk for infection through
percutaneous transmission was rare (3.8% among current, and 1.4% among past IDU partners,
respectively). Overall, the results of this study suggest that older age and lifetime history of drug
treatment are associated with a decrease in the odds of HCV disclosure.
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An association between age and disclosure has previously been identified in the HIV
literature,37,38 but not in the HCV literature. A recent study found that older adults (50 years
old) were less likely to disclose HIV than younger adults (20-39 years old).37 Post-hoc, genderstratified analyses in this study revealed that age was associated with HCV disclosure only
among women (p=0.006). These data suggest that older women are less likely as a group to
disclose their HCV-positive status than younger women, while age does not significantly
influence male disclosure patterns. The reasons for this are likely multifactorial, but may be
related to a greater perception of social stigma surrounding drug use among older women
compared to younger women or even men. A small, qualitative study of older (50 years of age)
HIV-positive women in the southeastern United States supports this hypothesis: the women
reported being reluctant to disclose their status because they viewed it as more shameful at their
older ages.38

The negative association between lifetime history of drug treatment and HCV disclosure had not
been identified in previous literature, and was an unexpected and novel finding of this study.
Although the nearly three-fold decrease in odds of disclosure among those with a lifetime history
of drug treatment seems counterintuitive, it is possible that individuals whose drug treatment was
court-ordered (as was the case in 52% with a lifetime history of drug treatment in the study) were
more reluctant to disclose their HCV-positive status out of fear that it would be seen as an
admission of prior or current drug use, which could violate their probation. Additionally,
individuals who successfully completed drug treatment may have a new social identity of being
abstinent, and might consider HCV disclosure irrelevant in their current milieu. The result
suggests that interventions aimed at increasing HCV disclosure should partner with drug
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treatment providers to clarify misperceptions among patients of the potential consequences and
benefits of disclosing one’s HCV serostatus.

This study is not without limitations. These data are cross-sectional; consequently, inferences
about causality or temporality are not possible. Second, as a result of the small sample size, the
analysis may have lacked the statistical power to detect small differences among some of the
covariates, potentially increasing the probability of type II error. Third, the homogeneity of this
rural, Appalachian sample may limit generalizability of the results to more diverse urban or rural
population groups. Similarly, the fact that this study population is in the midst of an acute HCV
epidemic3,28 may limit its generalizability beyond other settings experiencing increased acute
HCV incidence. Fourth, behavioral and demographic data were self-reported and subject to recall
and social desirability bias. Of note, HCV serostatus was not self-reported, and this was a
strength of the study. Fifth, information about disclosure in particular relationships (such as
duration of relationship or frequency of interaction) was not available. However, it does not
appear that the tendency to disclose to sex partners is related to frequency of contact, and on
average participants reported injecting more frequently in the prior 30 days than having sex.
Finally, serostatus in this study was based on HCV antibody testing rather than RNA testing;
antibody testing does not necessarily correlate with active HCV infection. However, a prior
random sample of HCV antibody-positive participants from the study cohort revealed that 69%
were HCV RNA-positive,39 suggesting a high potential for transmission and reinforcing the
importance of HCV disclosure, particularly to injection risk partners.
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Despite these limitations, this study provides important insight into demographic, behavioral, and
interpersonal correlates of HCV serostatus disclosure among high-risk drug users in rural
Appalachia. Most striking was the almost complete absence of disclosure to current or former
IDU partners, the social referents theoretically at highest risk of HCV infection given the
efficiency of percutaneous transmission. Current post-test counseling guidelines for HCV testing
do not mention disclosure.40 Incorporating educational messages related to the importance of
HCV disclosure into post-test counseling might help curtail the further spread of HCV. Findings
from this study suggest that messages targeted at older women should be prioritized since this
group was identified as being especially hesitant to disclose HCV status. Partnering with drug
treatment providers on interventions may represent another method to encourage HCV disclosure
as a normative behavior among those most at risk of transmitting, or becoming infected with,
HCV.
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Table 1. Demographic and behavioral characteristics of sample and univariate associations with
HCV disclosure (n=243)
Characteristic

Total n (%)

Disclosed
HCV-positive
status, n (%)

Crude
OR

95% CI

p-value

Demographic
Male
139 (57.2)
92 (54.8)
0.72
(0.41, 1.26)
0.251
Age (years), mean (SD)
33.8 (7.8)
33.2 (7.5)
0.97
(0.93, 1.00)
0.054
White
226 (93.0)
158 (94.1)
1.63
(0.59, 4.45)
0.344
High school graduate
132 (54.3)
90 (53.6)
0.91
(0.52, 1.57)
0.726
Currently married
46 (18.9)
35 (20.8)
1.53
(0.73, 3.21)
0.260
Unemployed
106 (43.6)
78 (46.4)
1.46
(0.83, 2.54)
0.188
Interpersonal
Spends most of free time
71 (29.2)
49 (29.2)
0.99
(0.55, 1.80)
0.979
alone
Social conflict
31 (12.8)
20 (11.9)
0.79
(0.36, 1.74)
0.552
Dependent on someone else 83 (34.2)
58 (34.5)
1.05
(0.59, 1.88)
0.857
for majority of support
Other characteristics
Lifetime history of IDU
215 (88.5)
144 (85.7)
0.34
(0.11, 1.01)
0.052
Lifetime history of drug
105 (43.2)
61 (36.3)
0.40
(0.23, 0.70)
0.001**
treatmenta
Time since HCV diagnosis
5.0 (3.5)
5.0 (3.7)
0.99
(0.92, 1.07)
0.764
(years), mean (SD)
HCV=Hepatitis C virus; OR=Odds ratio; CI=Confidence interval; SD=Standard deviation
a
Drug treatment includes methadone detoxification, methadone maintenance, Outpatient Drug
Free, residential treatment, non-methadone detoxification, and 12-step programs (Alcoholics
Anonymous/ Narcotics Anonymous)
**
p<0.01
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Table 2. Person-types to whom participants disclosed HCV-positive status (n=243)
Category
Disclosed HCV-positive status, n (%)
Current sex partner
107 (63.7)
Family member(s)
87 (51.8)
Close friend(s)
23 (13.7)
Past sex partner
16 (9.5)
a
Current injection drug use partners (n=72)
2 (3.8)
Spouse (if married) (n=46)b
1 (2.9)
c
Past injection drug use partners (n=215)
2 (1.4)
a
Calculated among the 72 participants who reported injection drug use in the past 6 months
b
Calculated among the 46 participants who were married
c
Calculated among the 215 participants who reported ever injecting drugs
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Table 3. Multivariate analysis of correlates to HCV disclosure (n=243)
Characteristic
Age
Lifetime history of drug treatment
Time since HCV diagnosis
OR=Odds ratio; CI=Confidence interval
*
p<0.05
**
p<0.01

Adjusted OR
0.96
0.39
1.01

95% CI
(0.93, 1.00)
(0.22, 0.69)
(0.93, 1.10)

p-value
0.043*
0.001**
0.782
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